Biologics for Long‑Term Urticaria: When to Start and What It Means

Veterans who suffer from chronic spontaneous urticaria (CSU) often endure numerous doctor visits, hospital stays, and emergency room trips before a new type of medicine—biologics—is tried. A decade‑long study examined records from 2011 to 2021 to track the journey from first diagnosis to biologic initiation and to quantify health‑care utilization.

Key Findings

• Population: 26,387 veterans were included in the analysis.
• Treatment Initiation:
• ~90 % began some form of treatment within a year.
• Only 2.6 % received a biologic drug.
• Time to Biologic:
• Median delay: 337 days (almost a year) from diagnosis to biologic therapy.
• Health‑Care Use Post‑Treatment:
• Pharmacy claims rose from 66.8 % pre‑treatment to 89.8 % post‑treatment.
• Outpatient visits increased from 92.4 % to 96.7 %.

Implications

These results suggest that clinicians might benefit from considering biologic therapy earlier for patients who meet the appropriate clinical profile. The marked increase in health‑care utilization after biologic initiation underscores how CSU can strain both patients and the medical system.